Patent intelligence · US
US 8712696
Methods of prognosing a rheumatoid arthritis remission phenotype
Methods of prognosing a rheumatoid arthritis remission phenotype
Patent details — US 8712696
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 29, 2014
- Expiration
- Apr 24, 2034
- Applicant
- PROGENIKA BIOPHARMA, S.A.
- Claims
- 20
- CPC classes
- A61P, A61P37/06
Quick answer
US 8712696 (Methods of prognosing a rheumatoid arthritis remission phenotype) is held by PROGENIKA BIOPHARMA, S.A.. Status: granted. Granted Apr 29, 2014. Expires Apr 24, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PROGENIKA BIOPHARMA, S.A.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61P, A61P37/06
More from PROGENIKA BIOPHARMA, S.A.
Related pharmaceutical patents in our USPTO index.
-
US 12415779
Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof
granted -
US 12391642
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12331026
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
granted -
US 12264167
Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors
granted -
US 12171741
2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12077506
Indane derivatives as hypoxia inducible factor-2(α) inhibitors
granted -
US 11939303
Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
granted -
US 11753366
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted
Frequently asked questions
What is US patent 8712696?
US 8712696 (Methods of prognosing a rheumatoid arthritis remission phenotype) is held by PROGENIKA BIOPHARMA, S.A.. Status: granted. Granted Apr 29, 2014. Expires Apr 24, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8712696?
PROGENIKA BIOPHARMA, S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.
When does US 8712696 expire?
Our index shows an expiration date of Apr 24, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.